Literature DB >> 17372715

[Stress proteins in prostate cancer. Challenge and promise].

B A Hadaschik1, S W Melchior, R D Sowery, A I So, M E Gleave.   

Abstract

Therapeutic resistance is the underlying basis for most cancer deaths. Exposure to anticancer therapies induces expression of many stress proteins, including heat shock proteins and clusterin. These molecular chaperones interact with various client proteins to assist in their folding and enhance cellular recovery from stress conditions. Cellular stress and cell death are linked, as the induction of chaperones appear to function at key regulatory points in the control of apoptosis. On this basis and on the role of stress proteins in the regulation of steroid receptors, kinases, caspases, and other protein remodeling events, it is not surprising that molecular chaperones have been implicated in resistance to anticancer treatments. Recently, several chaperones have been reported to be involved in development and progression of hormone-refractory prostate cancer. In this review, we address some of the events initiated by treatment-induced stress and discuss the potential role of chaperone inhibitors in prostate cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17372715     DOI: 10.1007/s00120-007-1323-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  30 in total

Review 1.  Role of the heat shock response and molecular chaperones in oncogenesis and cell death.

Authors:  C Jolly; R I Morimoto
Journal:  J Natl Cancer Inst       Date:  2000-10-04       Impact factor: 13.506

2.  Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.

Authors:  Palma Rocchi; Eliana Beraldi; Susan Ettinger; Ladan Fazli; Robert L Vessella; Colleen Nelson; Martin Gleave
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

3.  A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Authors:  Kim N Chi; Elizabeth Eisenhauer; Ladan Fazli; Edward C Jones; S Larry Goldenberg; Jean Powers; Dongsheng Tu; Martin E Gleave
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

4.  17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

Authors:  David B Solit; Fuzhong F Zheng; Maria Drobnjak; Pamela N Münster; Brian Higgins; David Verbel; Glenn Heller; William Tong; Carlos Cordon-Cardo; David B Agus; Howard I Scher; Neal Rosen
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

Review 5.  HSP90 and the chaperoning of cancer.

Authors:  Luke Whitesell; Susan L Lindquist
Journal:  Nat Rev Cancer       Date:  2005-10       Impact factor: 60.716

Review 6.  Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer.

Authors:  B Shannan; M Seifert; K Leskov; J Willis; D Boothman; W Tilgen; J Reichrath
Journal:  Cell Death Differ       Date:  2006-01       Impact factor: 15.828

7.  Binding of non-native protein to Hsp25 during heat shock creates a reservoir of folding intermediates for reactivation.

Authors:  M Ehrnsperger; S Gräber; M Gaestel; J Buchner
Journal:  EMBO J       Date:  1997-01-15       Impact factor: 11.598

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.

Authors:  Palma Rocchi; Alan So; Satoko Kojima; Maxim Signaevsky; Eliana Beraldi; Ladan Fazli; Antonio Hurtado-Coll; Kazuki Yamanaka; Martin Gleave
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

10.  Survivin expression is associated with features of biologically aggressive prostate carcinoma.

Authors:  Shahrokh F Shariat; Yair Lotan; Hossein Saboorian; Seyed M Khoddami; Claus G Roehrborn; Kevin M Slawin; Raheela Ashfaq
Journal:  Cancer       Date:  2004-02-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.